Table 4.
Summary of molecular glues under clinical evaluation for cancer therapy. Red: active, not recruiting; yellow: recruiting; blue: completed; violet: not yet recruiting. AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B cell lymphoma; GSPT1: G1 to S phase transition 1; IKZF: IKAROS zinc finger family; IRAK4: interleukin-1 receptor-associated kinase 4; MM: multiple myeloma; MyD88: myeloid differentiation primary response 88; NHL: non-Hodgkin’s lymphoma; NSCLC: non-small cell lung cancer; R/R: relapsed/refractory; SCLC: small cell lung cancer; SLL: small lymphocytic lymphoma.
| Time | Degrader | Target | Indication | NCT Number | Phase |
|---|---|---|---|---|---|
| 2011 2014 2015 2015 2015 2016 2017 2017 2017 |
Avadomide | IKZF1/3 | NHL, DLBCL, hepatocellular carcinoma, B-cell CLL, MM, CLL/SLL, follicular lymphoma, advanced solid tumors and melanoma |
NCT01421524
NCT02031419 NCT02417285 NCT02406742 NCT02509039 NCT02859324 NCT03310619 NCT03283202 NCT03834623 |
Phase I Phase I Phase I Phase I/II Phase I Phase I/II Phase I/II Phase I/II Phase II |
| 2016 2020 |
CC-90009 | GSPT1 | R/R AML or R/R higher-risk myelodysplastic syndromes |
NCT02848001
NCT04336982 |
Phase I Phase I |
| 2017 2019 2022 2022 2022 |
CC-92480 | IKZF1/3 | R/R MM |
NCT03374085
NCT03989414 NCT05372354 NCT05519085 NCT05552976 |
Phase I/II Phase I/II Phase I/II Phase III Phase III |
| 2017 2019 2020 2021 2021 |
CC-99282 | IKZF1/3 | R/R NHL and CLL/SLL |
NCT03310619
NCT03930953 NCT04434196 NCT04884035 NCT05169515 |
Phase I/II Phase I Phase I Phase I Phase I |
| 2021 | CFT7455 | IKZF1/3 | R/R NHL or MM | NCT04756726 | Phase I/II |
| 2019 | DKY709 | IKZF2/4 | Advanced solid tumors | NCT03891953 | Phase I |
| 2016 2017 2020 2020 2020 2021 2021 2021 2021 2021 2021 2021 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 |
Iberdomide | IKZF1/3 | Newly diagnosed MM, R/R MM, (smoldering) plasma cell myeloma and R/R lymphoma |
NCT02773030
NCT03310619 NCT04392037 NCT04464798 NCT04564703 NCT04776395 NCT04855136 NCT04998786 NCT04884035 NCT04934475 NCT04975997 NCT05169515 NCT05177536 NCT05199311 NCT05272826 NCT05289492 NCT05392946 NCT05354557 NCT05434689 NCT05527340 NCT05558319 NCT05560399 |
Phase I/II Phase I/II Phase II Phase I/II Phase II Phase II Phase I/II Phase II Phase I Phase III Phase III Phase I Phase II Phase I/II Phase II Phase I/II Phase I/II Phase II Phase I/II Phase II Phase II Phase I |
| 2022 | KT-413 | IRAK4 | R/R B-cell NHL and MYD88 mutant and MYD88 wild-type R/R DLBCL | NCT05233033 | Phase I |
| 2022 | MRT-2359 | GSPT1 | NSCLC, SCLC, high-grade neuroendocrine cancer of any primary site, DLBCL and tumors with L-MYC or N-MYC amplification | NCT05546268 | Phase I/II |